Invivyd, Inc. Files Q1 2025 10-Q
Ticker: IVVD · Form: 10-Q · Filed: May 15, 2025 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Invivyd's Q1 2025 10-Q is in. Check for updates on sales, R&D, and collaborations.
AI Summary
Invivyd, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Adagio Therapeutics, Inc., is involved in biological products. Key financial activities and agreements, such as sales agreements and collaborations like the Adimab Collaboration Agreement, are noted within this filing period.
Why It Matters
This filing provides investors with a quarterly update on Invivyd's financial health and operational activities, including details on agreements and expenses.
Risk Assessment
Risk Level: medium — As a company in the biological products sector, Invivyd faces inherent risks related to research, development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End (Quarterly financial reporting)
- 20250515 — Filing Date (Date the report was submitted)
Key Players & Entities
- Invivyd, Inc. (company) — Filer
- Adagio Therapeutics, Inc. (company) — Former company name
- 20250331 (date) — Reporting period end date
- 20250515 (date) — Filing date
- Adimab Collaboration Agreement (agreement) — Key collaboration mentioned
FAQ
What is the primary business of Invivyd, Inc.?
Invivyd, Inc. is primarily involved in Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When was Invivyd, Inc. formerly known as?
Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a date of name change on November 12, 2020.
What is the reporting period for this 10-Q filing?
The conforming period of report for this 10-Q filing is March 31, 2025.
What is the business address of Invivyd, Inc.?
The business address of Invivyd, Inc. is 1601 TRAPELO ROAD, SUITE 178, WALTHAM, MA 02451.
Are there any specific agreements mentioned in the filing data?
Yes, the filing data mentions several agreements including a Sales Agreement, Adimab Collaboration Agreement, and WuXi Commercial Manufacturing Services Agreement.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Invivyd, Inc. (IVVD).